Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
VALID Act of 2023
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
Matters pertaining to the VALID Act of 2023 (H.R.2369); Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses
VALID Act of 2023
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
Matters pertaining to the VALID Act of 2023 (H.R.2369); Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses; Docket No. FDA-2023-N-2177 (FDA's release of the Final Rule on LDTs
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
COALITION FOR INNOVATIVE LABORATORY TESTING, INC. via COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
2024 · third_quarter · Q3
Matters pertaining to the VALID Act of 2023 (H.R.2369); Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses; Docket No. FDA-2023-N-2177 (FDA's release of the Final Rule on LDTs
COALITION FOR INNOVATIVE LABORATORY TESTING, INC. via COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
2024 · second_quarter · Q2
Source: Senate LDA
VALID Act of 2023
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
Matters pertaining to the VALID Act of 2023 (H.R.2369); Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses; Docket No. FDA-2023-N-2177 (FDA's release of the Final Rule on LDTs
VALID Act of 2023
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2023 (H.R.2369); Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses
VALID Act of 2023
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2023 (H.R.2369); Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses
VALID Act of 2023
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2023 (H.R.2369); Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses
Electrodiagnostic Medicine Patient Protection and Fraud Elimination Act of 2023
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses; re-introduced in Spring of 2023 as H.R.2639
VALID Act of 2021
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses; re-introduced in Spring of 2023 as H.R.2639
VALID Act of 2021
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses; re-introduced in Spring of 2023 as H.R.2639
Consolidated Appropriations Act, 2023
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses FDASLA (S.4348); Provisions that negatively impact CLIA-approved laboratory businesses pertaining to the FDA's authority to collect certain fees and regulate certain products House User Fees (H.7667) Omni (H.R.2617)
VALID Act of 2021
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses
VALID Act of 2021
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses
VALID Act of 2021
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses FDASLA (S.4348); Provisions that negatively impact CLIA-approved laboratory businesses pertaining to the FDA's authority to collect certain fees and regulate certain products House User Fees (H.7667) Omni (H.R.2617)
VALID Act of 2021
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses FDASLA (S.4348); Provisions that negatively impact CLIA-approved laboratory businesses pertaining to the FDA's authority to collect certain fees and regulate certain products
VALID Act of 2021
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses FDASLA (S.4348); Provisions that negatively impact CLIA-approved laboratory businesses pertaining to the FDA's authority to collect certain fees and regulate certain products House User Fees (H.7667) Omni (H.R.2617)
VALID Act of 2021
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses
VALID Act of 2021
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses FDASLA (S.4348); Provisions that negatively impact CLIA-approved laboratory businesses pertaining to the FDA's authority to collect certain fees and regulate certain products
VALID Act of 2021
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses
FDASLA Act of 2022
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses FDASLA (S.4348); Provisions that negatively impact CLIA-approved laboratory businesses pertaining to the FDA's authority to collect certain fees and regulate certain products House User Fees (H.7667) Omni (H.R.2617)
FDASLA Act of 2022
Client: COALITION FOR INNOVATIVE LABORATORY TESTING, INC. · Firm: COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses FDASLA (S.4348); Provisions that negatively impact CLIA-approved laboratory businesses pertaining to the FDA's authority to collect certain fees and regulate certain products
Matters pertaining to the VALID Act of 2023 (H.R.2369); Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses; Docket No. FDA-2023-N-2177 (FDA's release of the Final Rule on LDTs
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, Small Business Administration (SBA)
COALITION FOR INNOVATIVE LABORATORY TESTING, INC. via COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
2024 · first_quarter · Q1
Matters pertaining to the VALID Act of 2023 (H.R.2369); Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR INNOVATIVE LABORATORY TESTING, INC. via COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
2023 · fourth_quarter · Q4
VALID Act of 2023 (H.R.2369); Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses
COALITION FOR INNOVATIVE LABORATORY TESTING, INC. via COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
2023 · third_quarter · Q3
VALID Act of 2023 (H.R.2369); Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR INNOVATIVE LABORATORY TESTING, INC. via COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
2023 · second_quarter · Q2
VALID Act of 2023 (H.R.2369); Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR INNOVATIVE LABORATORY TESTING, INC. via COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
2023 · first_quarter · Q1
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses; re-introduced in Spring of 2023 as H.R.2639
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR INNOVATIVE LABORATORY TESTING, INC. via COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
2022 · fourth_quarter · Q4
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses FDASLA (S.4348); Provisions that negatively impact CLIA-approved laboratory businesses pertaining to the FDA's authority to collect certain fees and regulate certain products House User Fees (H.7667) Omni (H.R.2617)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR INNOVATIVE LABORATORY TESTING, INC. via COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
2022 · third_quarter · Q3
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses FDASLA (S.4348); Provisions that negatively impact CLIA-approved laboratory businesses pertaining to the FDA's authority to collect certain fees and regulate certain products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR INNOVATIVE LABORATORY TESTING, INC. via COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
2022 · second_quarter · Q2
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR INNOVATIVE LABORATORY TESTING, INC. via COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
2022 · second_quarter · RA
VALID Act of 2021 (H.R.4128/S.2209; Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses